CD33 Splicing Polymorphism Is a Strong Predictor of Therapeutic Efficacy of Gemtuzumab Ozogamicin in De Novo AML: Report from COG-AAML0531 Study
| Image |  |
|---|---|
| Description | scholarly article |
| Author/s |
author: Richard Aplenc |
| Publication date | December 2, 2016 |
| Language | English |
| Country of origin | |
| Wikipedia link | |
| Access work | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |